Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Apathy, or lack of motivation, is increasingly recognised as a major factor a ecting quality of life and prognosis in Parkinson’s disease (PD). Impacting every stage of the disease, including de novo cases, reports have suggested it can a ect up to 70% of patients. Despite the pervasiveness of apathy in PD, challenges remain in its detection, clinical assessment, and treatment. Strong overlap with depression and anhedonia can complicate diagnosis, and although common features exist between all of these neuropsychiatric conditions, dissociations may be suggestive of di erent underlying brain mechanisms. Several lines of evidence have implicated frontostriatal reward and e ort-related neural pathways in the genesis of apathy, but the precise processes remain to be fully elucidated. The mainstay of current approaches in the treatment of apathy rely on dopamine replacement, although there is growing evidence that support a potential role for other agents. This paper reviews the current understanding of this important non-motor complication of PD.

Type

Journal article

Journal

European Medical Journal: Neurology

Keywords

Apathy, Parkinson's disease